Adverse outcomes in nontrial like patients on commercial HeartMate 3 LVAD support

Background: Patient selection for real-world use of HeartMate 3 left ventricular assist device (HM3 LVAD) differs from that of clinical trials. We assessed adverse-event rates between “nontrial like” (NTL) and “trial like” (TL) patients who underwent commercial HM3 implantation. Methods: We conducte...

Full description

Bibliographic Details

Published in:	JHLT Open Vol. 2; p. 100008
Main Authors:	Laura Coyle, APN, Colleen Gallagher, BSN, Nicole Graney, APN, Lisa Kukla, APN, Robin Paliga, APN, Kylie Hughes, APN, Rachel Pedersen, BA, Kathleen Schultz, APN, Adam JT Schuldt, MD, PhD, Nasir Sulemanjee, MD, Gregory P. Macaluso, MD, Sunil Pauwaa, MD, James Monaco, MD, Mark Dela Cruz, MD, William G. Cotts, MD, Nikhil Narang, MD, Patroklos S. Pappas, MD, Antone J. Tatooles, MD, Vinh Q. Chau, MD
Format:	Journal Article
Language:	English
Published:	Elsevier 01-12-2023
Subjects:	heart failure HeartMate 3 left ventricular assist device patient selection survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!